Biologic therapy for Psoriasis: A Brief History, I

Cutis

Volumn 68, Issue 5, 2001, Pages 331-336

  Weinberg, Jeffrey M ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; B3(FV) PE38KDEL RECOMBINANT IMMUNOTOXIN; B3(FV)-PE38KDEL RECOMBINANT IMMUNOTOXIN; CD4 ANTIGEN; IMMUNOTOXIN; PEPTIDE T;

BIOLOGICAL THERAPY; CLINICAL TRIAL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; PSORIASIS; REVIEW; TREATMENT OUTCOME;

ANTIBODIES; ANTIGENS, CD4; BIOLOGICAL THERAPY; CLINICAL TRIALS; HUMAN; IMMUNOTHERAPY; IMMUNOTOXINS; PEPTIDE T; PSORIASIS; TREATMENT OUTCOME;

EID: 0035514224     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Fitzpatrick TB, Johnson RA, Wolff K, et al. Color Atlas & Synopsis of Clinical Dermatology. 4th ed. New York, NY: McGraw Hill; 2001:50.
2. Barker JN. The pathophysiology of psoriasis. Lancet. 1991;338:227-230.
3. van De Kerkhof PC. New developments in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol. 2001;14:129-135.
4. Pert CB, Ruff MR. Peptide T[4-8]: a pentapeptide sequence in the AIDS virus envelope which blocks infectivity is essentially conserved across nine isolates. Clin Neuropharmacol. 1986;9(suppl 4H82-484.
5. Picone D, Rivieccio A, Crescenzi O, et al. Peptide T revisited: conformational mimicry of epitopes of antiHIV proteins. J Pept Sci. 2001;7:197-207.
6. Wetterberg L, Alexius B, Saaf J, et al. Peptide T in treatment of AIDS [letter]. Lancet. 1987;1:159.